SOURCE: OncBioMune Pharmaceuticals, Inc.

OncBioMune Pharmaceuticals, Inc.

June 06, 2017 09:40 ET

OncBioMune's Andfrt® Shown in Clinical Trial to Improve Sperm Count and Mobility

BATON ROUGE, LA--(Marketwired - June 06, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies and a proprietary vaccine technology and commercialization of a portfolio of products internationally, is pleased to report that the Company's licensed male fertility product Andfrt® demonstrated a clinically meaningful benefit in treating asthenozoospermia, a medical condition defined by abnormal sperm motility.

As disclosed on May 30, 2017, the Mexican Ministry of Health (MoH) recently authorized the commercialization of Andfrt®. Upon the approval, OncBioMune, through its 100%-owned Mexican subsidiary, immediately initiated the launch of Andfrt®, joining Bekunis® for constipation and Cirkused® for stress as products marketed by OncBioMune in the Mexican market.

In support of the MoH authorization, OncBioMune Mexico conducted an in-house clinical trial of Andfrt®, with the goal of evaluating the effect of the product on Mexican males with asthenozoospermia. In the 25-patient study (not statistically powered), the total count, mobility and morphology of the sperm had significant improvements in all subjects, as shown through analysis of variance (final visit) and multi-analysis of variance for repeated measurements (all visits).

"The results look very promising, especially given to the lack of competing available products versus Andfrt®. We are very much looking forward to treating our patients in short term with the new product," said Dr. Arturo Ramirez Muciño, a recognized urologist in Mexico.

"As Dr. Muciño succinctly points out, there is a great need for a product like Andfrt® in Mexico for the management of persistent asthenozoospermia," commented Dr. Jonathan Head, Chief Executive Officer at OncBioMune. "The product is already the leading male fertility product in Europe and we believe it will achieve similar success in Mexico under our brand, which is why we are moving expeditiously to distribute it to urologists and pharmacies across the country."

OncBioMune has rights to Andfrt® for the Mexican market through an exclusive license agreement with QPharma, Inc. QPharma markets the product in Europe under the brand name Androferti®. More information on Androferti® can be found at http://androferti.co.uk.

Sign up for OncBioMune email alerts at: http://oncbiomune.com/email-alerts/.

About OncBioMune Pharmaceuticals, Inc.

OncBioMune Pharmaceuticals is a revenue-stage biopharmaceutical company engaged the development of novel cancer immunotherapy products, including a proprietary vaccine technology designed to stimulate the immune system to attack tumor cells without damaging healthy tissue. OncBioMune is also involved in drug development and commercialization internationally through our wholly-owned subsidiary, OncBioMune México, S.A. De C.V. Our lead pipeline product, ProscaVax™, is scheduled to commence two, separate mid-stage clinical trials in 2017: a Phase 2 for early-stage prostate cancer at a major Northwest U.S. university cancer research hospital and a Phase 2/3 study in Mexico for late-stage prostate cancer patients. OncBioMune has a portfolio of targeted and licensed therapies, some of which are biosimilars and generics to blockbuster drugs. OncBioMune is headquartered in Baton Rouge, LA.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor there be any sale of these securities in any jurisdiction in which such offer solicitation or sale are unlawful prior to registration or qualification under securities laws of any such jurisdiction.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause OncBioMune Pharmaceuticals' actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. OncBioMune Pharmaceuticals has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are OncBioMune Pharmaceuticals' need for, and the availability of, substantial capital in the future to fund its operations and research and development; the fact that OncBioMune Pharmaceutical's vaccines and therapeutics may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in OncBioMune Pharmaceutical's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. OncBioMune Pharmaceuticals undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.

Contact Information